• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aadi Bioscience Inc.

    2/14/22 4:13:08 PM ET
    $AADI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email
    SC 13G 1 tm226174d4_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

     

    Aadi Bioscience, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    00032Q104

    (CUSIP Number)

     

    August 26, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 00032Q104 Page 2 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     

    CUSIP No. 00032Q104 Page 3 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     

    CUSIP No. 00032Q104 Page 4 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     

     CUSIP No. 00032Q104 Page 5 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                       

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     

     

    CUSIP No. 00032Q104 Page 6 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

      

     

     

     CUSIP No. 00032Q104 Page 7 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

                 

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     CUSIP No. 00032Q104 Page 8 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

     

                 

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

    CUSIP No. 00032Q104 Page 9 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

    CUSIP No. 00032Q104 Page 10 of 17

     

               
    1.  

    Name of Reporting Persons

     

    Shah, Nimish

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

    CUSIP No. 00032Q104 Page 11 of 17

     

               
    1.  

    Name of Reporting Persons

     

    Koh, Bong

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    1,529,4022

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    1,529,4022

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,529,4022

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    7.3%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 20,894,029 shares of the Issuer’s Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021.

     

     

     

     

    CUSIP No. 00032Q104 Page 12 of 17

     

    Introductory Note: This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Aadi Bioscience, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Aadi Bioscience, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    17383 Sunset Boulevard, Suite A250

    Pacific Palisades, CA 90272

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

     

     

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share

     

      (e) CUSIP Number

     

    00032Q104

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of December 31, 2021:

     

    Venrock Healthcare Capital Partners II, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings II, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners III, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings III, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,529,402(1)
    VHCP Management II, LLC   1,529,402(1)
    VHCP Management III, LLC   1,529,402(1)
    VHCP Management EG, LLC   1,529,402(1)
    Nimish Shah   1,529,402(1)
    Bong Koh   1,529,402(1)

     

      (b) Percent of Class as of December 31, 2021:

     

    Venrock Healthcare Capital Partners II, L.P.   7.3%
    VHCP Co-Investment Holdings II, LLC   7.3%
    Venrock Healthcare Capital Partners III, L.P.   7.3%
    VHCP Co-Investment Holdings III, LLC   7.3%
    Venrock Healthcare Capital Partners EG, L.P.   7.3%
    VHCP Management II, LLC   7.3%
    VHCP Management III, LLC   7.3%
    VHCP Management EG, LLC   7.3%
    Nimish Shah   7.3%
    Bong Koh   7.3%

     

      (c) Number of shares as to which the person has, as of December 31, 2021:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

     

     

    CUSIP No. 00032Q104 Page 14 of 17

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings II, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners III, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings III, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,529,402(1)
    VHCP Management II, LLC   1,529,402(1)
    VHCP Management III, LLC   1,529,402(1)
    VHCP Management EG, LLC   1,529,402(1)
    Nimish Shah   1,529,402(1)
    Bong Koh   1,529,402(1)

     

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings II, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners III, L.P.   1,529,402(1)
    VHCP Co-Investment Holdings III, LLC   1,529,402(1)
    Venrock Healthcare Capital Partners EG, L.P.   1,529,402(1)
    VHCP Management II, LLC   1,529,402(1)
    VHCP Management III, LLC   1,529,402(1)
    VHCP Management EG, LLC   1,529,402(1)
    Nimish Shah   1,529,402(1)
    Bong Koh   1,529,402(1)

     

    (1) Consists of (i) 246,692 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 100,023 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 533,456 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 53,376 shares held by VHCP Co-Investment Holdings III, LLC and (v) 595,855 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

     

    CUSIP No. 00032Q104 Page 16 of 17

     


    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ David L. Stepp
    Its: General Partner   Name: David L. Stepp
        Its: Authorized Signatory
    /s/ David L. Stepp    
    Name:   David L. Stepp    
    Its:   Authorized Signatory    

     

    Bong Koh    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    
         
    Nimish Shah    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

     

     

     

    CUSIP No. 00032Q104 Page 17 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement

     

    B: Power of Attorney for Nimish Shah

     

    C: Power of Attorney for Bong Koh

     

     

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Aadi Bioscience, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 14th day of February, 2022.

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name:   David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ David L. Stepp
    Its: General Partner   Name: David L. Stepp
        Its: Authorized Signatory

    /s/ David L. Stepp    
    Name: David L. Stepp    
    Its: Authorized Signatory    

     

    Bong Koh    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

    Nimish Shah    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

     

     

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 14th day of February, 2022.

     

    /s/ Nimish Shah  

     

     

     

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 14th day of February, 2022.

     

    /s/ Bong Koh  

     

     

    Get the next $AADI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AADI

    DatePrice TargetRatingAnalyst
    8/27/2024$5.00 → $1.75Overweight → Neutral
    Piper Sandler
    8/21/2024$11.00 → $1.50Buy → Hold
    Jefferies
    8/21/2024Buy → Hold
    TD Cowen
    12/15/2023Buy → Neutral
    H.C. Wainwright
    1/11/2022$45.00Buy
    Jefferies
    11/24/2021$47.00 → $49.00Buy
    HC Wainwright & Co.
    10/1/2021Outperform
    Cowen & Co.
    9/14/2021$51.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AADI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aadi Bioscience downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and set a new price target of $1.75 from $5.00 previously

      8/27/24 7:14:32 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by Jefferies with a new price target

      Jefferies downgraded Aadi Bioscience from Buy to Hold and set a new price target of $1.50 from $11.00 previously

      8/21/24 3:41:58 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience downgraded by TD Cowen

      TD Cowen downgraded Aadi Bioscience from Buy to Hold

      8/21/24 7:18:26 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Aadi Bioscience Inc.

      SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)

      10/1/24 5:35:56 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/3/24 5:51:01 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aadi Bioscience Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      8/28/24 4:42:02 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Leadership Updates

    Live Leadership Updates

    See more
    • Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

      Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of 2023 LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathwa

      10/2/23 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.  The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.    The details of the poster presentations are below: Title

      4/26/23 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

      LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. The presentations at AACR 2023 include: a trials-in-progress (TIP) poster for the ongoing PRECISION 1 trial, a registrational directed tumor agnostic study for patients with solid tumors driven by TSC1 or TSC2 alterations; results on the anti-tumor activity of nab-s

      4/14/23 1:09:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    SEC Filings

    See more
    • SEC Form S-8 filed by Aadi Bioscience Inc.

      S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/28/25 4:53:43 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

      3/26/25 8:21:16 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Aadi Bioscience, Inc. (0001422142) (Filer)

      3/18/25 4:38:49 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Closing of $100 Million PIPE Financing

      MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592

      3/4/25 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

      MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si

      3/3/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dalal Anupam was granted 1,561,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/5/25 7:51:57 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Castelein Caley was granted 1,666,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 7:24:11 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      3/4/25 6:14:13 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AADI
    Financials

    Live finance-specific insights

    See more
    • Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update

      MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected]  View original content to download multimedia:https://w

      3/14/25 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

      LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience  Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L

      10/30/24 4:05:00 PM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

      FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex

      8/7/24 8:00:00 AM ET
      $AADI
      Biotechnology: Pharmaceutical Preparations
      Health Care